Newbury Pharmaceuticals AB
SSTO:NEWBRY1.72
SEK
+0.01
(+0.58%)
ISIN
SE0015244884
Return %
Stock
S&P 500
1Y
-25.54
14.20
3Y
-43.23
81.12
5Y
- -
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Karl Alexius Tiger Karlsson
- Full Time Employees
- 7
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Medicon Village Lund SN Sweden 223 81
- IPO Date
- Feb 4, 2022
- Website
- newburypharma.com
- Similar Companies
- Business
- Newbury Pharmaceuticals AB (publ) (NEWBRY.ST) operates as a hybrid pharmaceutical company focused on developing, licensing, and marketing specialty prescription drugs in the Scandinavian market, primarily Sweden and Denmark. The company offers a diversified portfolio of branded and generic products across key therapeutic areas including oncology treatments for solid and hematological malignancies such as breast cancer, myeloma, leukemia, prostate cancer, and thyroid cancer; rare disease therapies characterized by high treatment costs and low patient volumes; neurology agents with an emphasis on multiple sclerosis alternatives; and individual products in various indications aligned with its specialty pharmaceuticals strategy. Its existing portfolio targets an annual sales value of approximately EUR 800 million in Scandinavia, with oncology, rare diseases, and neurology comprising over 50% of the focus, serving healthcare providers, hospitals, and patients through commercial activities like marketing authorizations, distribution, and launches. Founded in 2020 and headquartered in Lund, Sweden, Newbury Pharmaceuticals builds its pipeline via proprietary developments and strategic licensing while acting as a local alternative to multinational firms. Recent developments include a directed share issue in April 2025 raising approximately SEK 16 million from investors such as Life Science Invest Fund and existing shareholders to fund regulatory processes, new license fees, milestones, and working capital for product launches and growth; an extension of its SEK 15 million loan to June 2026; expansion of its distribution partnership with Amarox Limited by adding four registered products; and a prior 2023 agreement with Amarox for six products in Sweden and Denmark, alongside securing marketing authorizations for 32 products with 14 launched as of early 2025.